XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Segment information
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment information

13.        Segment information

The Company views its operations and manages its business in one operating segment: life science. The table below summarizes the significant expense categories for the life science segment regularly reviewed by the CODM for the three months ended March 31, 2025 and 2024:

Three months ended March 31,

2025

    

2024

Total revenues

$

1,176,096

$

210,118

Less:

Cost of Product, Collaboration and License Sales

7,707

5,195

Program Spend

48,158

48,364

Employee Costs

67,699

63,997

Manufacturing Costs

14,950

18,081

Administrative Costs

18,414

16,872

Occupancy Costs

7,183

9,893

Other segment items (a)

145,423

139,292

Segment Net Income (Loss)

$

866,562

$

(91,576)

Reconciliation of profit or loss

Adjustments and reconciling items

Consolidated Net Income (Loss)

$

866,562

$

(91,576)

(a)Other segment items includes the following:

Three months ended March 31,

2025

2024

Interest income

$

(17,245)

$

(10,940)

Interest expense

51,337

51,774

Income tax expense

63,266

6,880

Depreciation

3,458

3,867

Amortization

3,798

51,530

All other (b)

40,809

36,181

Total other segment items

$

145,423

$

139,292

(b)All other includes COGS royalty, travel and expense, distribution costs, bad debt expense, finance costs, contract labor costs, stock compensation expense, change in the fair value of contingent consideration, and other (expense) income.